Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 1
1985 1
1986 1
1987 4
1988 1
1989 3
1990 1
1993 3
1994 1
1995 4
1996 1
1997 3
1998 2
1999 4
2000 5
2001 7
2002 6
2003 14
2004 23
2005 21
2006 27
2007 23
2008 35
2009 29
2010 31
2011 31
2012 41
2013 72
2014 71
2015 84
2016 96
2017 74
2018 61
2019 77
2020 85
2021 73
2022 55
Text availability
Article attribute
Article type
Publication date

Search Results

972 results
Results by year
Filters applied: . Clear all
Page 1
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT; DISCOVER-1 Study Group. Deodhar A, et al. Among authors: xu xl. Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178765 Free article. Clinical Trial.
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group. Mease PJ, et al. Among authors: xu xl. Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178766 Clinical Trial.
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD, Xu XL, Subramanian RA, Agarwal P, Sheng S, Jiang Y, Zhou B, Zhuang Y, van der Heijde D, Mease PJ. McInnes IB, et al. Among authors: xu xl. Arthritis Rheumatol. 2021 Apr;73(4):604-616. doi: 10.1002/art.41553. Epub 2021 Mar 17. Arthritis Rheumatol. 2021. PMID: 33043600 Free PMC article. Clinical Trial.
Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis.
Yu Y, Peng XD, Qian XJ, Zhang KM, Huang X, Chen YH, Li YT, Feng GK, Zhang HL, Xu XL, Li S, Li X, Mai J, Li ZL, Huang Y, Yang D, Zhou LH, Zhong ZY, Li JD, Deng R, Zhu XF. Yu Y, et al. Among authors: xu xl. Signal Transduct Target Ther. 2021 Dec 1;6(1):401. doi: 10.1038/s41392-021-00790-2. Signal Transduct Target Ther. 2021. PMID: 34848680 Free PMC article.
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY, Kong PF, Xia LP, Huang Y, Li ZL, Tang YY, Chen YH, Li X, Senthilkumar R, Zhang HL, Sun T, Xu XL, Yu Y, Mai J, Peng XD, Yang D, Zhou LH, Feng GK, Deng R, Zhu XF. Wu RY, et al. Among authors: xu xl. Clin Cancer Res. 2019 Jul 15;25(14):4530-4541. doi: 10.1158/1078-0432.CCR-18-2840. Epub 2019 Apr 2. Clin Cancer Res. 2019. PMID: 30940655
972 results